Loading...
XHEL
BIOBV
Market cap40mUSD
Oct 07, Last price  
2.39EUR
1D
1.27%
1Q
-10.82%
Jan 2017
-60.50%
Name

Biohit Oyj

Chart & performance

D1W1MN
XHEL:BIOBV chart
P/E
13.26
P/S
2.31
EPS
0.18
Div yield, %
—
Shrs. gr., 5y
0.20%
Rev. gr., 5y
17.12%
Revenues
16m
+9.79%
31,408,00032,751,00034,805,00035,366,00040,044,00039,922,0002,048,0003,452,0004,363,0006,051,0008,195,0008,979,0009,931,00010,052,0007,123,0009,361,00010,951,00013,076,00014,300,00015,700,000
Net income
3m
+5.31%
-839,000-1,502,000897,000387,00061,00037,710,000-3,656,000-5,917,000-1,161,000-2,917,000-3,295,0006,139,000-2,143,000-1,416,000-3,312,000-1,500,000601,0001,851,0002,600,0002,738,000
CFO
-700k
L
100,0001,040,0001,188,0002,796,0001,961,0004,957,000-8,890,000-4,443,000-3,435,000-3,147,000-2,457,000-943,000-93,00083,000-25,000-444,0001,848,000902,000586,000-700,000
Dividend
Apr 15, 20140.7234 EUR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Helsinki-based Biohit Oyj is a biotechnology company that specializes in developing and distributing diagnostic tests and analytical systems worldwide for healthcare providers and research institutions. Their comprehensive portfolio of diagnostic solutions includes the GastroPanel test, designed for evaluating stomach conditions and associated risks, alongside tests for active vitamin B12 levels (Biohit Active B12) and vitamin D status (Biohit Total). They also offer the Biohit Calprotectin test, various methods for detecting Helicobacter pylori infection from biopsy samples, the ColonView Quick Test for identifying fecal occult blood, rapid tests for Lactose Intolerance and Celiac Disease, and the GA-map Dysbiosis test for detailed gut microbiota DNA analysis. Beyond diagnostics, Biohit manufactures products that bind carcinogenic acetaldehyde into harmless compounds, such as Acetium capsules for individuals with low stomach acidity, and Acetium lozenges, which neutralize acetaldehyde in smokers' saliva. The company also supplies monoclonal antibodies crucial for research in cellular pathology, neurobiology, oncology, and human gastric biomarkers. Additionally, their offerings extend to laboratory instrumentation, including microplate readers, strip washers, quick test readers, and the ThunderBolt automated immunoassay analyzer, complemented by comprehensive service laboratory provisions. Biohit Oyj was founded in 1988.

Key people

Lea Paloheimo
Independent Chairman of the Board · since 2022
Graham Johnson
Managing Director of Biohit Healthcare Ltd. · since 2011
Ilari Patrakka
Sales and Marketing Director, Member of the Management Team · since 2016
Annika Astola
Quality Director, Member of the Management Team · since 2014
Suvi Elomaa
Production Manager, Member of the Management Board · since 2021
Jussi Hahtela
Chief Executive Officer, Member of the Management Board · since 2022
Panu Hendolin
Head - Research & Development, Member of the Management Board · since 2022
Daniela Soderstrom
Quality and Regulatory Affairs Director, Member of the Management Team · since 2016
Jussi Sorvo
Chief Financial Officer, Member of the Management Board · since 2022
Franco Aiolfi
Director, Managing Director of Biohit Healthcare S.r.l.
Liu Feng
Director · since 2018
Matti Harkonen
Director · since 2017
Osmo Suovaniemi
Chairman of the Board, Deputy Chief Executive Officer · since 2021
Kalle Harkonen
Independent Director · since 2022
Eero Lehti
Independent Director · since 2009
IPO date
Jun 18, 1999
Employees
42
Domiciled in
FI
Incorporated in
FI
Headquarters & legal address
LAIPPATIE 1
00880 HELSINKI
HELSINKI FI-00880
FI

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT